Entrinsic Health Solutions and Markey Cancer Center Present Clinical Data in Patients with Neuroendocrine Tumors at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
— enterade® can reduce diarrhea in cancer patients leading to improved quality of life —
NORWOOD, Mass., February 28, 2018 – Entrinsic Health Solutions in partnership with the Markey Cancer Center, today announced clinical data from a pilot study examining the anti-diarrheal efficacy of enterade®, an amino acid based solution, in neuroendocrine tumor (NET) patients. Aman Chauhan, MD, Hematology and Oncology Fellow at the University of Kentucky, presented the results during a poster session titled, “The Anti-diarrheal Efficacy of an Amino Acid Mixture in Neuroendocrine Tumor (NET) Patients” at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium held in San Francisco from January 18 – 20, 2018.
The purpose of the study was to evaluate if enterade® could help boost gastrointestinal (GI) function and reduce diarrhea frequency in 33 NET patients. A total of 33 subjects were treated and efficacy data was available on 17 of those subjects by the time of the presentation. Results concluded that 76% (13/17) of neuroendocrine tumor patients reported improvement in diarrhea with enterade® and 76.9% (10/13) reported more than 50% reduction in diarrhea frequency after one week of treatment. With no sugar to exacerbate GI dysfunction, enterade® can reduce diarrhea related to cancer treatment, leading to an improvement in patients’ overall quality of life and a healthier GI system.
“More than 100,000 people in the United States are living with neuroendocrine cancers and many suffer from long-term, chronic diarrhea, which is a debilitating condition. Furthermore, current treatment options are limited for these patients,” said Dorothy Keefe, MD, Chief Medical Officer, Oncology at Entrinsic Health Solutions. “This study validates previous scientific findings and further demonstrates that enterade® may reduce diarrhea related to cancer treatment, thereby improving the lives of these patients. Follow-up prospective clinical trials are needed to build on this data.”
“Being able to potentially offer another therapeutic alternative with a new class of agents to this group of patients suffering from chronic symptoms is exciting,” said Dr. Chauhan, Fellow at the University of Kentucky Healthcare Markey Cancer Center.
A prospective Phase II study of enterade® in gastroenteropancreatic neuroendocrine tumor patients with quality of life limiting diarrhea is planned. The poster presentation is available in the News & Media section of the Entrinsic Health Solutions website at www.entrinsichealth.com.
enterade® is a first-in-class, glucose-free medical food that is composed of five critical amino acids (Valine, Aspartic Acid, Serine, Threonine, Tyrosine) and electrolytes (potassium and sodium) to help manage debilitating gastrointestinal (GI) side effects. With no sugar to exacerbate the GI dysfunction, enterade® supports the small bowel’s ability to absorb fluids, nutrients, and electrolytes and leads to improved digestive function. By helping to restore normal GI function, enterade® reduces diarrhea and dehydration, leading to a significant improvement in the patient’s overall quality of life and a healthier GI tract. For more information, please visit us at www.enterade.com and connect with the brand on Facebook, Instagram, and Twitter.
About Entrinsic Health Solutions
Entrinsic Health Solutions, Inc., is an innovative health sciences company dedicated to the development and commercialization of amino acid based medical foods to address critical digestive health, nutrition and hydration related health issues. The Company’s proprietary Amino Acid Coupled Transport (A₂CT) Technology platform leverages gold-standard science and game-changing amino acid technology to address critical digestive and hydration-related health issues. A2CT technology uses select amino acids to facilitate active transport of electrolytes throughout the body, which delivers rapid hydration, decreased gut permeability and improved nutrient absorption, supporting long-term digestive health. For more information, please visit us at www.entrinsichealth.com.
About University of Kentucky Markey Cancer Center
Markey Cancer Center has provided state-of-the-art cancer care for more than 20 years, and is the only cancer center in Kentucky designated by the National Cancer Institute. In August 2017, Markey was designated as one of the Top 50 Cancer Centers in the nation by U.S. News & World Report. Its expert teams of physicians, nurses and other health care providers have experience working with patients in a compassionate and caring environment.